{"filings":[{"id":2107356,"accession_number":"0001193125-26-338321","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-08-06T20:45:35+00:00","items":["1.01","9.01"],"status":"ready","headline":"Organogenesis enters $75M at-the-market equity distribution agreement with BTIG and Citizens JMP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M of Class A common stock may be sold from time to time through BTIG and Citizens JMP Securities.","Agents receive a 3% commission on the gross sales price per share sold under the agreement.","Company has no obligation to sell any shares; sales are at its discretion based on market conditions.","Shares will be sold on Nasdaq Capital Market via at-the-market offerings under Rule 415(a)(4).","Agreement includes customary indemnification; terminates upon termination per its terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2106039,"accession_number":"0001193125-26-338022","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-08-06T20:11:52+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.","Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.","Adjusted EBITDA loss $34.4M vs $3.6M loss; operating loss $51.0M vs $12.6M.","FY 2026 revenue guidance cut to $179M-$215M (62-68% decline) from prior 45-52% decline.","Cash $46.8M, no debt; CEO cites slower-than-expected market recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1084836,"accession_number":"0001193125-26-272710","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-06-16T20:32:55+00:00","items":["5.02","5.07"],"status":"ready","headline":"Organogenesis shareholders elect 9 directors, approve say-on-pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 9 director nominees elected; Glenn H. Nussdorf received lowest support (61M for, 24.3M withheld).","Advisory say-on-pay approved with 72.5M for, 12.7M against, 61k abstentions.","Ratification of RSM US LLP as auditor for FY2026 approved with 128.4M votes for.","Series A Preferred holders re-elected Garrett Lustig to board via written consent.","129.6M shares present or represented at the June 15, 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94499,"accession_number":"0001661181-26-000007","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.","Net loss $53.2M ($0.44/sh) vs $18.8M loss ($0.17/sh) in Q1 2025; adjusted net loss $43.7M.","Adjusted EBITDA loss $48.2M vs $12.5M loss; gross margin collapsed to 29% from 73%.","FY2026 revenue guidance $270M-$310M, decline of 45%-52% from $564.2M in 2025.","Cash $92.1M, no debt; expects sequential improvement in Q2 and strong H2 growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":37228000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106927,"accession_number":"0001193125-26-076595","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).","Q4 net income $43.7M ($0.25/sh) vs $7.7M ($0.04/sh) a year ago; Adj. EBITDA $84.2M.","FY2025 net product revenue $563.0M (+17% YoY); net income $37.0M vs $0.9M in FY2024.","FY2026 total net revenue guidance $350M - $420M, a 25% to 38% decline from FY2025; expects Q1 drop then sequential growth.","Cash and equivalents $94.3M with no outstanding debt as of Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":564169000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106926,"accession_number":"0001193125-26-064270","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Organogenesis appoints Patrick McGuire as CAO; Francisco remains CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick McGuire, 40, appointed Chief Accounting Officer and principal accounting officer effective Feb 18, 2026; was VP Corporate Controller since Sep 2023.","Annual base salary raised to $345,000; no other compensation changes.","David Francisco ceases as principal accounting officer but stays as CFO and principal financial officer.","McGuire is a CPA and previously held roles at Cynosure (controller) and PwC (director)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123253,"accession_number":"0001193125-25-335425","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Organogenesis extends Canton lease terms through 2032 with related-party landlords; rent escalates 3% annually","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended leases at 65 Dan Road and 150 Dan Road from Dec 31, 2027 to Dec 31, 2032, with an option to extend to Dec 31, 2034.","2027 annual rent: $1.61M (65 Dan Road) and $3.16M (150 Dan Road); first renewal year rent = 103% of 2027 rent or fair market value.","Audit Committee approved related-party transactions with >5% holders Alan Ades, Albert Erani, Dennis Erani, Glenn Nussdorf (director), and Robert Ades (director).","Rent increases 3% per year after first renewal year; appraisal/arbitration process if tenant rejects landlord's fair market determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123252,"accession_number":"0001193125-25-269654","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).","Net income $21.6M ($0.11 diluted EPS) vs $12.3M ($0.09) YoY; adjusted net income $23.2M.","Adjusted EBITDA $30.1M vs $13.4M YoY; operating income $20.7M vs $6.2M.","FY2025 revenue guidance raised to $500-525M (4-9% YoY); Adj. net income guided $21.5-38.4M.","Cash $64.4M, no debt; cash down from $136.2M due to operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":338562000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139932,"accession_number":"0001193125-25-217810","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).","ReNu showed numerical improvement in baseline pain reduction vs first Phase 3 (-6.9 vs -6.0); safety profile favorable.","Statistically significant maintenance of function (p<0.0001) reported in second study.","Company to request pre-BLA meeting with FDA by end of October 2025 to discuss combined efficacy from both Phase 3 trials.","First Phase 3 met primary endpoint (difference -0.7, p=0.0177); ReNu has FDA RMAT designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139931,"accession_number":"0000950170-25-105032","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.","Net loss $9.4M ($0.10 per share) vs $17.0M loss a year ago; adjusted net loss $7.5M vs income $0.2M.","FY2025 guidance: revenue $480-510M (flat to +6%); adjusted EBITDA $31.1-61.9M.","Fourth Amendment to Credit Agreement waives Q2 2025 covenant test; must reset covenants by Sept 30, 2025; no additional borrowing until then.","Cash and restricted cash $73.7M, no debt; expects cash plus product sales to fund ops for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":187698000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157533,"accession_number":"0001193125-25-145767","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.","All nine director nominees elected; Garrett Lustig re-elected via Series A written consent with vote tallies of ~72M for.","Advisory 'say-on-pay' proposal approved with 67.1M votes for, 6.3M against.","Ratification of RSM US LLP as independent auditor for FY2025 passed with 103.6M votes for, 3.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157532,"accession_number":"0000950170-25-066930","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.","Net loss $18.8M ($0.17 loss per share) vs $2.1M loss in Q1 2024; adjusted EBITDA loss $12.5M vs income $2.6M.","Cash $110.5M, no debt; cash used in operations $19.9M vs $10.2M in prior year.","FY2025 revenue guidance reaffirmed at $480M-$535M; updated net income guidance $4.7M-$34.0M (from prior range).","ReNu BLA submission on track for end of 2025; second phase 3 study patient enrollment expected by end of Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":86693000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175908,"accession_number":"0001193125-25-065638","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organogenesis posts investor presentation with no disclosed material changes; details unavailable","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted investor presentation to its website on March 27, 2025.","Presentation is current as of March 27, 2025; no obligation to update.","No financial or operational specifics from the presentation were provided in the filing.","Presentation attached as Exhibit 99.1 but content not fully reproduced in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175907,"accession_number":"0000950170-25-029021","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).","Q4 net income $7.7M ($0.05 diluted EPS) vs net loss $0.6M; adjusted net income $8.8M vs $1.9M.","FY24 revenue $482.0M (+11%); net income $0.9M vs $4.9M; adjusted net income $20.5M vs $12.7M.","Cash $136.2M, zero debt (vs $104.3M cash and $66.2M net debt year-end 2023).","FY25 guidance: revenue $480-535M; net income $9.5-38.8M; Adj. EBITDA $43.6-83.2M; ReNu BLA submission targeted by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":482043000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192817,"accession_number":"0000950170-24-132248","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Organogenesis repurchases 500K shares from director trust at $4.057/sh for $2M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchase of 500,000 shares from GN 2016 Family Trust (related to director Glenn Nussdorf) at $4.057/share, total $2.03M.","Price based on 10-day trailing VWAP of common stock as of Nov 26, 2024.","Repurchase approved by Audit Committee and a Transaction Committee of the Board due to related-party nature.","Funded by proceeds from Nov 12, 2024 sale of Series A Convertible Preferred Stock to Avista Healthcare Partners.","Closing expected on or around December 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192816,"accession_number":"0000950170-24-130202","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Organogenesis signs 16.5-year lease for 122,000 sq ft RI biomanufacturing facility, base rent $43/sq ft from 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased 122,000 sq ft at 100 Technology Way, Smithfield, RI for biomanufacturing expansion.","Initial term ~16.5 years through May 2041; two 10-year renewal options.","Base rent $43/sq ft starting June 2026, 3% annual escalations; triple net lease.","Lease contingent on state/local tax incentives; termination right with $1.25M payment if not secured by March 2025.","Company continues to operate Canton, MA HQ and other facilities in US and Switzerland."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192815,"accession_number":"0001193125-24-256699","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","5.03","2.04","3.02","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.","Net proceeds used for strategic growth, debt repayment, and repurchase of 7.4M common shares from directors at $3.1597/share (~$23.5M).","Preferred pays 8% annual dividend, compounded quarterly, payable in cash or PIK; conversion price initially $3.7917 (20% premium).","Company expects to prepay ~$62.5M term loan principal and interest on Nov 13, 2024, using offering proceeds.","Appointed Garrett Lustig (Avista Principal) to Board, increasing board size to twelve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192814,"accession_number":"0000950170-24-125331","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).","GAAP net income $12.3M ($0.09 diluted EPS) vs $3.2M ($0.02) YoY.","Adjusted EBITDA $13.4M, down from $16.0M; Non-GAAP operating income $7.1M vs $11.0M.","Cash $94.9M, net debt $62.1M; FY guidance: rev $455-480M, adj net income $6.7-18.4M.","CEO cites brand equity and work with policymakers on access solution."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":355387000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209240,"accession_number":"0000950170-24-093893","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).","Net loss $17.0M ($0.13/sh) vs net income $5.3M Q2 2023; included $18.8M impairment and $4.0M software write-down.","Adjusted EBITDA essentially flat at $15.6M; adjusted net income fell to $0.2M from $6.1M.","FY2024 revenue guidance reaffirmed $445-$470M; net loss guided $(27)-$(12)M; Adj. EBITDA $16-$35M.","Cash $90.5M, debt $63.5M; management cites near-term variability in skin substitutes market."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":240210000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227177,"accession_number":"0001193125-24-165670","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 15.9M share increase to 2018 Equity Incentive Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; votes ranged from 41.5M to 68.4M for, with broker non-votes of 39.3M.","Advisory vote on executive compensation passed with 63.8M for, 5.9M against.","Amendment to 2018 Equity Incentive Plan adding 15,900,000 shares approved (52.0M for, 17.7M against).","Ratification of RSM US LLP as independent auditor for FY2024 passed (106.4M for, 2.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227176,"accession_number":"0000950170-24-056885","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.","Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).","GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.","FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.","Cash $89.3M, debt $64.9M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":109976000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227175,"accession_number":"0001193125-24-086129","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court dismisses securities fraud lawsuit against Organogenesis, CEO and CFO with prejudice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Eastern District of New York granted motion to dismiss on March 29, 2024.","All claims against Organogenesis, CEO, and CFO dismissed with prejudice, preventing refiling.","Lori Freedman, Chief Administrative and Legal Officer, expressed satisfaction with the ruling.","No financial impact or settlement amount disclosed in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246062,"accession_number":"0000950170-24-023059","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).","Q4 net loss $0.6M vs net income $7.5M; adjusted net income $1.9M vs $8.9M.","FY2023 net income $4.9M vs $15.5M; adjusted EBITDA $42.6M vs $49.3M.","FY2024 revenue guidance $445M-$470M (3%-9% growth); net income (loss) range ($10.6M)-$4.6M.","Management highlights progress on ReNu program for knee osteoarthritis as key value driver."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":433140000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263520,"accession_number":"0000950170-23-062041","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q3 revenue down 7% to $108.5M; net income rises to $3.2M; guides FY rev down 1-4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $108.5M, down $8.3M YoY; Advanced Wound Care fell 7% to $101.4M; Surgical & Sports Med fell 2% to $7.2M.","Net income $3.2M ($0.02/sh) vs $0.2M ($0.00/sh) in Q3 2022; adjusted net income $5.3M vs $5.1M.","Adjusted EBITDA $16.0M, up 38% from $11.6M; operating income $8.1M vs $1.8M.","FY2023 guidance: net revenue $433-446M (down 1-4% YoY); net income $4-9M; adjusted net income $11-17M.","Revenue impacted by LCD withdrawal issues; profitability improved despite headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":333489000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280741,"accession_number":"0000950170-23-040643","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue $117.3M (-3% YoY); withdraws FY2023 guidance on Medicare LCDs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $117.3M, down 3% YoY from $121.4M; net income $5.3M vs $8.7M.","Adjusted net income $6.1M, adjusted EBITDA $15.4M; both down YoY.","Withdrew FY2023 guidance due to Medicare LCDs from Novitas, First Coast Services, CGS limiting DFU/VLU coverage to only Apligraf and Dermagraft effective Sept 17, 2023.","Cash and equivalents $89.5M, debt $69.0M as of June 30.","Company engaging with relevant parties regarding LCDs; uncertain impact on revenue outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":224958000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299356,"accession_number":"0001193125-23-168964","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Organogenesis shareholders elect 11 directors, approve say-on-pay, ratify RSM as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; Glenn Nussdorf had 23.3M withhold (35.6%) and Arthur Leibowitz 20.3M withhold (31.0%).","Advisory vote on executive compensation passed: 51.7M for, 13.7M against, 64.6K abstain.","Ratification of RSM US LLP as auditor approved: 101.5M for, 238.8K against, 86.0K abstain.","Broker non-votes of 36.4M shares on director election and say-on-pay items.","101.8M shares represented at the meeting, out of total outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299355,"accession_number":"0000950170-23-020572","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.","Advanced Wound Care revenue $100.9M (+12% YoY); Surgical & Sports Medicine $6.7M (-4% YoY).","Adjusted EBITDA $3.8M vs $5.0M prior year; adjusted net loss $0.7M.","FY2023 guidance raised: revenue $454-466M, net income $3-11M, adjusted EBITDA $38-49M.","Cash $88.7M, debt $69.9M at March 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":107642000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319511,"accession_number":"0000950170-23-005554","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q4 revenue down 10% YoY; FY2023 guidance flat to +2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net revenue $115.5M (-10% YoY); net income $7.5M vs $51.0M in Q4 2021.","FY2022 net revenue $450.9M (-4% YoY); net income $15.5M vs $94.2M in FY2021.","FY2023 guidance: revenue $450-462M (flat to +2%); net income $7.2-13.9M.","PuraPly revenue expected to decline 18-26% in FY2023 to $180-200M.","Adjusted EBITDA FY2023 guidance $36.5-46.0M vs $49.3M in FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":450893000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337703,"accession_number":"0000950170-22-023902","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.","Adjusted EBITDA $11.6M, down 46% YoY; adjusted net income $5.1M, down 68%.","FY2022 revenue guidance lowered to $448-465M, citing challenging physician office environment and reimbursement uncertainty.","SG&A expenses surged 27% to $79.3M, pressuring margins.","Cash $108M, debt $72.6M; no share repurchase or dividend changes."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":335377000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355085,"accession_number":"0001193125-22-216156","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue $121.4M (-1% YoY); net income falls 58% to $8.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $121.4M vs $123.2M in Q2 2021; adjusted revenue up 3% excluding ReNu/NuCel.","Net income $8.7M ($0.07 diluted EPS) vs $20.7M ($0.15) a year ago; Adjusted net income $11.3M.","Advanced Wound Care rev $113.8M (+2%), Surgical & Sports Medicine $7.6M (-35%).","PuraPly rev $69.4M (+84%); non-PuraPly $52.0M (-39%).","FY2022 guidance: net revenue $465M-$490M; Adj. EBITDA $60M-$74M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":218518000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373169,"accession_number":"0001193125-22-182860","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Organogenesis stockholders approve director removal amendment and equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Incorporation amended to allow director removal without cause by majority vote.","2018 Equity Incentive Plan share reserve increased by 7,826,970 shares.","All 11 director nominees elected; advisory say-on-pay approved with 91.7M for, 12.6M against.","Stockholders selected 1-year frequency for future advisory say-on-pay votes.","Ratification of RSM US LLP as auditor for FY2022 received 117.0M for, 141k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373168,"accession_number":"0001193125-22-146299","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.","Surgical & Sports Medicine revenue fell 39% to $7.2M due to ReNu/NuCel discontinuation.","PuraPly revenue grew 29% to $53.3M, partially offsetting declines.","Adjusted EBITDA $5.0M, down 69% from $16.0M; cash at $108.5M.","FY2022 guidance: net revenue $485M-$515M, net income $41.2M-$52.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":98117000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373167,"accession_number":"0001193125-22-142414","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Organogenesis appoints Michele Korfin and Gilberto Quintero to board as independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michele Korfin appointed as independent director; brings experience from Gamida Cell, Kite Pharma, Celgene.","Gilberto Quintero appointed as independent director; serves as Chief Quality Officer at Kimberly-Clark, formerly at Cardinal Health.","Each director receives $55,000 annual retainer and 23,913 RSUs vesting May 3, 2023.","Board expands to 11 members, with majority now independent under Nasdaq standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373166,"accession_number":"0001193125-22-106925","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Organogenesis sets 2022 annual meeting for June 23; expands board to 11 members","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2022 Annual Meeting scheduled for June 23, 2022; record date April 25, 2022.","Board increased from 9 to 11 directors; two independent directors to be appointed by May 6, 2022.","Deadline for stockholder proposals and director nominations is April 25, 2022.","Board expansion addresses Nasdaq independence requirement after losing controlled-company status on May 6, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391920,"accession_number":"0001193125-22-061346","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).","Q4 GAAP net income $51.7M ($0.39 diluted EPS) vs $18.3M ($0.15) a year ago; adjusted EBITDA $26.3M.","FY2021 net revenue $468.1M (+38% YoY); net income $94.9M ($0.71 diluted EPS); adjusted EBITDA $89.1M.","FY2022 guidance: net revenue $485M-$515M (+4% to +10% YoY); net income $56.5M-$71.5M; adjusted EBITDA $79.9M-$95.3M.","Cash and equivalents $114.5M; total debt $73.6M as of Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":468059000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391919,"accession_number":"0001193125-22-046638","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Organogenesis appoints Michael J. Driscoll to board as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Driscoll appointed independent director effective Feb 15, 2022, expanding board to nine members.","He will serve on audit and nominating committees; receives $72,500 annual retainer.","Received an award of 20,547 RSUs vesting Feb 15, 2023.","Driscoll brings 28 years in financial services and 10 years in academia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410227,"accession_number":"0001193125-21-370607","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2021-12-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Organogenesis shareholders elect 8 directors and ratify RSM US LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected: Alan A. Ades, Robert Ades, Duraibabu, Erani, Giacomin, Gillheeney, Leibowitz, Nussdorf.","Ratification of RSM US LLP as independent auditor for fiscal 2021 passed with 94,296,655 votes for, 181,675 against.","95,954,171 shares of Class A common stock represented at the December 29, 2021 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410226,"accession_number":"0001193125-21-336764","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Organogenesis appoints Prathyusha Duraibabu to board, regains Nasdaq audit committee compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Prathyusha Duraibabu appointed independent director effective Nov 19, 2021; also joins audit committee.","Board now has eight members; appointment restores compliance with Nasdaq Listing Rule 5605(c)(2)(A).","Ms. Duraibabu received 11,340 RSUs vesting in equal annual installments over three years.","She is CFO of Sangamo Therapeutics; brings 24+ years in tech/healthcare and CPA qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410225,"accession_number":"0001193125-21-324457","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q3 revenue $113.8M (+13% YoY), net income $12.6M, FY2021 guidance $458-470M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $113.8M (+13% YoY); Advanced Wound Care $107.3M (+19%), Surgical & Sports Medicine $6.4M (-41%).","Net income $12.6M ($0.09 diluted EPS) vs $20.8M ($0.19) in Q3 2020; adj. EBITDA $21.7M (19% margin).","FY2021 guidance: net revenue $458-470M (35-39% growth); Advanced Wound Care $425-434M, PuraPly $196-204M.","Cash $102.7M, debt $83.2M as of Sept 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":339501000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429059,"accession_number":"0001193125-21-247828","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Organogenesis buys Canton facility for $6M from directors/stockholders; terminates lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased land and building at 275 Dan Road, Canton, MA for $6M cash from seller owned by directors/stockholders.","Also agreed to pay deferred rent of ~$5.06M plus accrued interest ~$1.05M over installments with 4.5% annual simple interest.","Existing lease dated Jan 1, 2013 terminated with no penalties; transaction approved by Audit Committee.","Seller entity owned by Alan Ades, Dennis Erani, and Glenn Nussdorf; Ades and Nussdorf are on Organogenesis board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429058,"accession_number":"0001193125-21-240438","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue $123.2M (+79%), net income $20.7M; new $200M credit facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $123.2M (+79% YoY); Advanced Wound Care $111.4M (+87%), Surgical & Sports Med $11.8M (+27%).","Net income $20.7M ($0.15 diluted EPS) vs loss $5.2M; adjusted EBITDA $25.1M (20.4% of revenue).","FY2021 revenue guidance raised to $456-472M (35-40% growth); GAAP net income and adjusted EBITDA positive.","New $200M credit facility ($75M term loan + $125M revolver) with LIBOR-based pricing; prior facility terminated.","Legacy stockholders agreed not to sell shares until March 1, 2022 unless via underwritten secondary offering."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":225748000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}